2023 ESC Guidelines for the management of cardiomyopathies
The first dedicated ESC cardiomyopathy guideline introduces a phenotype-based classification spanning HCM, DCM, the new non-dilated left ventricular cardiomyopathy (NDLVC), restrictive and arrhythmogenic right ventricular cardiomyopathy. The register's landmark trials for hypertrophic cardiomyopathy and cardiac amyloidosis are grouped below.
This guideline cites 4 of the 199 landmark trials in our Cardiology register.
Hypertrophic cardiomyopathy — cardiac myosin inhibitors2
- 2022VALOR-HCMCardiology · HF · myosin inhibitorA Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Eligible for Septal Reduction Therapy
- 2020EXPLORER-HCMCardiology · HF · myosin inhibitorClinical Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cardiac amyloidosis (ATTR)1
- 2018ATTR-ACTCardiology · HF · CardiomyopathyTafamidis in Transthyretin Amyloid Cardiomyopathy
Sudden-death prevention (ICD)1
- 2016DANISHCardiology · Arrhythmia · ICDDanish Study to Assess the Efficacy of ICDs in Non-Ischaemic Systolic Heart Failure
Published since the guideline2
- 2024SEQUOIA-HCMCardiology · HF · myosin inhibitorSafety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM
- 2024ATTRibute-CMCardiology · HF · TTR stabiliserEfficacy and Safety of Acoramidis (AG10) in Subjects With Transthyretin Amyloid Cardiomyopathy